Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10086457 | 0.86 | NPC1 (0.47) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL1608759 | 0.84 | PTGES (0.42) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL10085490 | 0.78 | NPC1 (0.65) | NPC1RAB9APKMMEN1KMT2A | |
| SCHEMBL10085782 | 0.78 | MCHR1 (0.46) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL1609263 | 0.78 | PTGES (0.40) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL1609194 | 0.78 | CYP11B1 (0.47) | HTR2CNPC1RAB9APKMMEN1 | |
| SCHEMBL10085927 | 0.77 | NPC1 (0.44) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL10086549 | 0.77 | NPC1 (0.44) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL18470574 | 0.77 | NPC1 (0.59) | HTR2CNPC1RAB9APKMHTR2A | |
| SCHEMBL13113373 | 0.76 | LPAR5 (0.44) | HTR2CNPC1RAB9APKMHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | HTR2C 258/4885NPC1 558/4885RAB9A 555/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | HTR2C 325/4885NPC1 1824/4885RAB9A 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.